Lung Cancer Treatment Denied by Insurance: How to Appeal

Lung cancer is the leading cause of cancer death in the United States, yet patients fighting it routinely face insurance denials for the very treatments that have transformed survival outcomes over the past decade. Immunotherapy agents like pembrolizumab (Keytruda) and nivolumab (Opdivo), targeted therapies for EGFR and ALK mutations, and even low-dose CT screening for high-risk individuals are among the most frequently denied services. These denials are often reversible with the right appeal.

The Landscape of Lung Cancer Treatment Denials

Immunotherapy: Keytruda and Opdivo

Pembrolizumab is FDA-approved as first-line monotherapy for non-small cell lung cancer (NSCLC) with PD-L1 expression of 50% or higher (TPS ≥ 50), and in combination with chemotherapy for a wider range of PD-L1 expression levels. Nivolumab has approvals across multiple NSCLC and SCLC lines of therapy.

Insurers commonly deny these agents by:

• Requiring PD-L1 testing documentation, then denying based on strict cutoff interpretation
• Arguing a lower-cost chemotherapy-only regimen is "equivalent"
• Demanding Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization approval before each infusion cycle, then slow-walking decisions
• Labeling combination IO+chemo as investigational despite FDA approval

Targeted therapy: EGFR, ALK, ROS1, KRAS G12C

For patients with actionable mutations — EGFR exon 19 deletions or L858R, ALK rearrangements, ROS1 fusions, or KRAS G12C mutations — targeted therapies (osimertinib, alectinib, sotorasib, adagrasib) are standard of care per NCCN guidelines. Insurers may deny:

• Biomarker testing itself, delaying identification of who qualifies
• Later-generation agents (osimertinib third-generation EGFR TKI) citing availability of earlier agents
• Approved agents for earlier-stage adjuvant use, where evidence is strong but newer

Low-Dose CT Screening (LDCT)

The USPSTF recommends annual LDCT screening for adults aged 50–80 with a 20-pack-year smoking history who currently smoke or quit within the past 15 years. Under the ACA, this is an A-rating recommendation requiring coverage at no cost-sharing for qualifying individuals. Despite this, many insurers deny LDCT screening by:

• Applying outdated age or pack-year criteria (the pre-2021 USPSTF criteria)
• Coding the visit incorrectly, triggering cost-sharing
• Requiring the order come from a specific provider type

Why "Not Medically Necessary" Is Rarely Accurate

Lung cancer denials often use the phrase "not medically necessary" — but in practice, this means the insurer's reviewer applied a different clinical standard than your oncologist. The legal standard for medical necessity under most plans is whether the treatment is consistent with generally accepted standards of medical practice. When your oncologist is recommending an FDA-approved, NCCN Category 1-supported regimen, that standard is met by definition.

Your Rights Under Federal and State Law

ACA protections: No lifetime or annual dollar limits on essential health benefits. Cancer treatment is a covered EHB category. LDCT screening must be covered at zero cost-sharing for qualifying patients.

Step therapy laws: At least 30 states have enacted step therapy override statutes. These laws typically require an insurer to grant an override when step therapy creates clinically contraindicated delays. In lung cancer, where certain mutations make standard chemo inferior, step therapy requirements are often legally overridable.

External Independent Review: Complete Guide" class="auto-link">External review rights: If your internal appeal is denied, you have the right to request independent external review by an IROs) Explained" class="auto-link">Independent Review Organization (IRO). IRO reviewers are board-certified physicians. External reviews overturn insurer decisions in 30–40% of cases across all conditions — and significantly higher rates for cancer.

ERISA plans: Employer-sponsored plans are governed by ERISA. You must exhaust internal appeals before suing, but courts increasingly scrutinize insurer denials in cancer cases where clinical guidelines are clear.

Building a Winning Appeal

A lung cancer appeal should include:

1. Pathology and molecular testing reports confirming diagnosis, histology (adenocarcinoma, squamous cell, SCLC), and biomarker results (PD-L1 TPS, EGFR, ALK, ROS1, KRAS status)
2. NCCN Clinical Practice Guidelines printout for the relevant cancer type and recommended regimen — cite the specific category of evidence
3. Letter of medical necessity from your oncologist or thoracic oncology specialist explaining why the denied treatment is standard of care and why alternatives are inferior
4. FDA prescribing information confirming the approved indication matches your clinical situation
5. Peer-reviewed literature — key trials like KEYNOTE-024, FLAURA, ALEX trial if relevant

Make the denial's logic explicit and then refute each element. If the insurer cites lack of medical necessity, show that their own coverage criteria and NCCN align with the prescribed treatment. If they cite step therapy, check your state's override law.

Fight Back With ClaimBack

ClaimBack provides lung cancer patients with a structured, evidence-driven appeal process. We help you gather the right clinical documentation, frame your argument in the language insurers and external reviewers respond to, and submit your appeal correctly.

Start your appeal at ClaimBack

An insurance denial is not the end. With the right appeal, many lung cancer patients successfully overturn these decisions and resume treatment without delay.

Related Reading

• What Is Medical Necessity?
• Internal vs. External Insurance Appeals
• Common Reasons Insurance Claims Are Denied